Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells
- 1 November 2017
- journal article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 335, 16-27
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Environmental Health Sciences (R15ES026789)
- National Institutes of Health ((1R15ES026789-01))
This publication has 69 references indexed in Scilit:
- AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutationsBMC Cancer, 2016
- Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations.2016
- Synergistic interaction between MEK inhibitor and gefitinib in EGFR-TKI-resistant human lung cancer cellsOncology Letters, 2015
- Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells2015
- ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescenceThe FEBS Journal, 2009
- Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell lineLung Cancer, 2009
- Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivoCancer Research, 2009
- A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancerGynecologic Oncology, 2008
- Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?Nature Reviews Cancer, 2007
- Molecular Context of theEGFRMutations: Evidence for the Activation of mTOR/S6K SignalingClinical Cancer Research, 2006